FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.
Page 2 of 34
Aug 25, 2026Abramson told STAT that the ecosystem should expect clarity on generative AI through future FDA documents. The message is less about immediate rule changes than about the agency moving from general discussion to a defined policy framework for a technology category that developers increasingly need mapped to regulatory expectations.
Dr. Priya Nandakumar
Aug 25, 2026Capricor’s original Aug. 22 action date passed without a decision, and the company now says the FDA classified its latest submission as a major amendment. Strategically, the amendment shifts the center of gravity back to the trial’s primary endpoint after a contentious review process that spent substantial time on a cardiac-related secondary endpoint.
Michael Torres
Aug 24, 2026RGX-121 had regained a possible path under accelerated approval in June after the FDA earlier rejected the filing and asked for a new study, more patients and a placebo arm. The new hold shifts the focus from filing strategy back to safety interpretation and longer-term follow-up in an ultra-rare disease setting with limited imaging history.
Emily Carter
Aug 24, 2026BioSpace reported that experts see the FDA’s handling of Replimune’s advanced melanoma therapy and Capricor’s Duchenne muscular dystrophy filing as evidence that the agency is moving past the Makary-Prasad period. That does not amount to broad leniency: companies preparing submissions still face the same need to narrow interpretive gaps and align early with the agency.
Daniel Cho
Aug 24, 2026STAT reported that the working paper, which has not yet been peer-reviewed, estimates the drop equals about 34 fewer 12-ounce cans of soda per person per year and could reduce type 2 diabetes risk by 2.6% over the next 10 years. The same study also found that recipients redirected up to 39% of the forgone soda spending to other sugary beverages and were more likely to report feeling judged or disrespected.
Jonathan Blake
Aug 21, 2026Reps. John Moolenaar and Ben Cline reportedly asked Acting FDA Commissioner Kyle Diamantas to reject clinical data from China unless a trial site has recently undergone an FDA audit, and to review products already approved using clinical results from China. The pressure comes after at least three patient deaths were reported over the last few months in trials in China, including a Duchenne muscular dystrophy study run by HuidaGene.
Dr. Alex Morgan
Aug 21, 2026STAT said trust has become central to its mission after the Covid-19 pandemic and amid what it called a defining crisis in science. The publication hired Nicholas Florko to lead a new reporting beat focused on misinformation, how it spreads, and what can be done to counter it.
Emily CarterMuscle dysmorphia is currently categorized under obsessive-compulsive and related disorders, even though it often involves extreme dieting and other eating-related behaviors. Nagata argues that moving it into the eating disorder framework would better match how patients present in practice, while critics say the existing classification is already accurate and can be paired with an eating disorder diagnosis when appropriate.
Emily CarterNow executive director of The Evidence Collective, Marnik has become a visible vaccine communicator on Instagram, Substack and in public talks. Her story points to a strategic issue in public health communication: strong evidence may be necessary, but sources and messengers still shape whether people hear it.
Dr. Priya NandakumarMultiple reports said Trump had chosen or was expected to choose Heidi Overton, deputy director of the White House Domestic Policy Council, as the next FDA commissioner. For drug developers and investors, the immediate issue is less the optics of the pick than whether a confirmed commissioner can restore predictability to an agency that has been operating with acting leadership since Marty Makary’s departure in May.
Jonathan Blake
Aug 19, 2026The Council on Education for Public Health has not finalized its next competency framework, but draft changes have already exposed a dispute over whether public health education is adapting to varied legal environments or preemptively retreating from explicit language on racism. The outcome matters beyond curriculum design because accreditation standards determine what dozens of schools and nearly two hundred programs must demonstrate in order to keep their standing.
Michael Torres
Aug 19, 2026Dauphin County’s recent property tax increases offer one local example of a broader fiscal squeeze hitting state and local governments. With public employers often constrained by union expectations, fixed budgets, and political resistance to tax hikes, the story suggests health benefit inflation is becoming a structural policy issue rather than a negotiable line item.
Jonathan BlakeMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.